The place of Zoladex in deferred surgery for uterine fibroids. Zoladex Myoma Study Group.

Abstract

Two hundred and forty-seven patients with uterine fibroids were randomized to surgery alone or 3 months' Zoladex (Zeneca, Macclesfield, Ches., UK) followed by surgery. Zoladex significantly reduced uterine and fibroid volumes (p = 0.0001). There was a significantly (p = 0.002) greater mean rise in haemoglobin from entry to preoperation in the Zoladex group (1 g/dl) compared with the surgery-alone group (0.3 g/dl) as well as a tendency towards easier surgery, and reduced operative blood loss. Zoladex-treated patients had a significantly (p = 0.016) shorter hospital stay and pelvic pain and abdominal pressure symptoms were significantly (p < 0.0001) reduced in this group. Zoladex was well tolerated.

• Authors: J Gerris, M Degueldre, A A Peters, F Romao, M Stjernquist, H al-Taher
• Journal: Hormone research (Horm Res) Vol. 45 Issue 6 Pg. 279-84 ( 1996) ISSN: 0301-0163 [Print] Switzerland
• PMID: 8793522 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents, Hormonal
• Hemoglobins
• Goserelin

Topics

• Adult
• Antineoplastic Agents, Hormonal (therapeutic use)
• Combined Modality Therapy
• Female
• Goserelin (administration & dosage, adverse effects, therapeutic use)
• Hemoglobins (metabolism)
• Humans
• Leiomyoma (drug therapy, pathology, surgery)
• Length of Stay
• Premedication
• Prospective Studies
• Uterine Neoplasms (drug therapy, pathology, surgery)
• Uterus (pathology)